Matthew is a Senior Early-Phase Chemistry, Manufacturing and Controls (CMC) Consultant with more than 13 years in the CMC sector. He has successfully led CMC development activities on numerous projects from the identification of a suitable drug candidate, through to phase 2 clinical trials.
Matthew received his B.S. in Chemistry, with a minor in psychology, from Rensselaer Polytechnic Institute in upstate New York. He later received his Ph. D. in Organic Chemistry from U.C. Berkeley for his work on the total synthesis of natural products with Professor Clayton Heathcock. Upon graduating in 2001, he immediately began his career in the pharmaceutical industry working for GlaxoSmithKline starting in a traditional Chemical Development role before expanding to lead early-phase CMC development activities.
Matthew’s primary experience is in the development of robust, cost-effective synthetic routes and methodologies that can reproducibly deliver quality API to the customer. He uses a risk-based approach to deliver customized development plans that balance speed, resource cost, and long-term program risks to maximize value for the team. He also has experience leading early-phase formulation development activities, and utilizing extemporaneous compounding to quickly move projects into the clinic at a reduced cost. This enables the project to clear a major hurdle in the drug development life cycle before committing significant resource to traditional development activities. Additionally, he has directed the development and manufacture of several single-phase amorphous dispersions of API in a polymer matrix to enhance bioavailability, and has experience in setting up laboratories for continuous processing / flow chemistry and scaling them into the pilot plant.